Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

CARE-MS | Investigators, Raymond Hupperts

Research output: Contribution to journalArticleAcademicpeer-review

757 Citations (Web of Science)


Background the anti-cd52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
Original languageEnglish
Pages (from-to)1829-1839
Issue number9856
Publication statusPublished - 24 Nov 2012

Cite this